These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1505 related items for PubMed ID: 23542346

  • 1. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [Abstract] [Full Text] [Related]

  • 2. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
    Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.
    J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of telaprevir, pegylated interferon α-2b and ribavirin triple therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Kawaguchi Y, Iwane S, Kumagai T, Yanagita K, Yasutake T, Ide Y, Otsuka T, Eguchi Y, Ozaki I, Akiyama T, Kawazoe S, Mizuta T.
    Intern Med; 2015 Oct; 54(20):2551-60. PubMed ID: 26466688
    [Abstract] [Full Text] [Related]

  • 4. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.
    Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N.
    J Hepatol; 2012 Jan; 56(1):78-84. PubMed ID: 21827730
    [Abstract] [Full Text] [Related]

  • 5. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.
    Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1076-85. PubMed ID: 24099469
    [Abstract] [Full Text] [Related]

  • 6. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M, Furusyo N, Ogawa E, Mitsumoto F, Hiramine S, Ikezaki H, Takayama K, Shimizu M, Toyoda K, Kainuma M, Hayashi J.
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response.
    Furusyo N, Ogawa E, Murata M, Toyoda K, Ohnishi H, Eiraku K, Shimizu M, Harada Y, Mitsumoto F, Takayama K, Kainuma M, Okada K, Hayashi J.
    J Antimicrob Chemother; 2014 Feb; 69(2):483-90. PubMed ID: 24092661
    [Abstract] [Full Text] [Related]

  • 8. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
    Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S.
    World J Gastroenterol; 2016 Mar 28; 22(12):3418-31. PubMed ID: 27022224
    [Abstract] [Full Text] [Related]

  • 9. Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy.
    Sood A, Midha V, Goyal O.
    Ann Hepatol; 2014 Mar 28; 13(5):503-9. PubMed ID: 25152982
    [Abstract] [Full Text] [Related]

  • 10. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
    Aziz H, Raza A, Waheed Y, Gill U, Gill ML.
    Int J Infect Dis; 2012 Aug 28; 16(8):e597-602. PubMed ID: 22658873
    [Abstract] [Full Text] [Related]

  • 11. Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy.
    Nakagawa A, Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Arai T, Hashimoto S, Matsushita Y, Fukuda T, Nakatsuka K, Iwakiri K, Kawamoto C, Aizawa Y, Sakamoto C.
    Eur J Gastroenterol Hepatol; 2014 Dec 28; 26(12):1329-34. PubMed ID: 25357216
    [Abstract] [Full Text] [Related]

  • 12. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.
    Tsubota A, Shimada N, Atsukawa M, Abe H, Kato K, Ika M, Matsudaira H, Nagatsuma K, Matsuura T, Aizawa Y.
    J Gastroenterol Hepatol; 2014 Jan 28; 29(1):144-50. PubMed ID: 24117654
    [Abstract] [Full Text] [Related]

  • 13. Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.
    Kawakami Y, Suzuki F, Karino Y, Toyota J, Kumada H, Chayama K.
    Antivir Ther; 2014 Jan 28; 19(3):277-85. PubMed ID: 24192751
    [Abstract] [Full Text] [Related]

  • 14. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
    Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M.
    Biomed Pharmacother; 2011 Jul 28; 65(4):303-6. PubMed ID: 21723079
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.
    Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Oshita M, Mita E, Ito T, Inui Y, Inada M, Tamura S, Yoshihara H, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hayashi N, Takehara T.
    J Viral Hepat; 2015 Mar 28; 22(3):254-62. PubMed ID: 25081140
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 76.